8-K: Kodiak Sciences' Zenkuda & Tabirafusp-ted Meet Phase 3 Endpoints

Kodiak Sciences announced that its Phase 3 DAYBREAK study met primary endpoints for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration (wAMD).

Summary

• Kodiak Sciences Inc. announced that its Phase 3 DAYBREAK study met primary endpoints for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in patients with wet age-related macular degeneration (wAMD).
• Zenkuda demonstrated meaningful vision gains and rapid, sustained retinal drying, with 54% of patients on a 6-month dosing interval using strict treat-to-dryness criteria.
• Zenkuda met its primary endpoint with a p-value of 0.0007, showing strong immediacy and durability, positioning it as a potential new standard-of-care.
• Tabirafusp-ted met the vision primary endpoint (p-value of 0.0036) and an anatomical key secondary endpoint (p-value of <0.0001).
• The company plans to submit a multi-indication biologics license application (BLA) for Zenkuda in Q4 2026, covering five positive Phase 3 studies across wAMD, diabetic retinopathy, and retinal vein occlusion.
• Safety profiles for both Zenkuda and tabirafusp-ted were consistent with aflibercept.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, with strong clinical trial results for two key drug candidates, indicating significant progress towards potential regulatory approval and commercialization.

Positives

• Both Zenkuda and tabirafusp-ted met their primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration (wAMD).
• Zenkuda demonstrated strong immediacy of clinical effect, matching or exceeding aflibercept during the loading phase.
• Zenkuda showed strong durability, with 54% of patients achieving 6-month dosing intervals at year one under strict treat-to-dryness criteria.
• Zenkuda's safety profile was favorable, with a 0% intraocular inflammation rate and a 0.5% cataract adverse event rate.
• Tabirafusp-ted met its vision primary endpoint (p=0.0036) and anatomical key secondary endpoint (p<0.0001).
• Tabirafusp-ted also demonstrated a favorable safety profile with a 0.4% intraocular inflammation rate and 0% cataract adverse event rate.
• Kodiak plans to submit a BLA for Zenkuda in Q4 2026, supported by five positive Phase 3 studies.
• The company is accelerating tabirafusp-ted development for diabetic macular edema (DME) in the ongoing ALTO Phase 3 study.

Negatives

• While non-inferiority was met, Zenkuda's vision gains were comparable to aflibercept, not superior, during the loading phase.
• The filing does not provide specific comparative efficacy data for tabirafusp-ted against aflibercept beyond meeting primary and secondary endpoints.

Risks

• The Phase 3 studies for Zenkuda may not be sufficient to support a BLA submission or approval in DR, RVO, or wet AMD.
• A BLA for tarcocimab tedromer or any other product candidate may not be accepted by, or receive approval from, the FDA or foreign regulatory agencies when expected, or at all.
• Cessation, modification, or delay of any ongoing clinical studies and Kodiaks development of Zenkuda, KSI-501, KSI-101, or any other product candidate may occur.
• Safety, efficacy, and durability data observed in Kodiaks product candidates in current or prior studies may not continue or persist.
• KSI-501 may not inhibit VEGF and IL-6 or have an impact on the treatment of patients as expected.
• The PEAK Phase 3 study for KSI-101 may not achieve its primary endpoint or may not do so on the anticipated timeline.
• Sufficient capital may not be available to complete the development of any products.
• Adverse conditions in the U.S. and global economic markets may significantly impact Kodiaks business and operations.

Future Outlook

Kodiak Sciences plans to submit a multi-indication BLA for Zenkuda in Q4 2026, covering five positive Phase 3 studies. They also anticipate topline data for KSI-101 in December 2026 and plan to submit a BLA for KSI-101 in Q2 2027. The development of tabirafusp-ted for diabetic macular edema is accelerating with the ALTO Phase 3 study enrolling patients.

Management Comments

• "The strength of these DAYBREAK data positions us for the next stage of Kodiaks evolution, as we prepare for the planned commercialization of Zenkuda as a potential best-in-class therapy for patients with wet AMD, diabetic retinopathy and retinal vein occlusion."
• "The results generated in DAYBREAK with tabirafusp-ted are also highly encouraging, and we are enthusiastic to explore the potential for tabirafusp-ted to demonstrate superiority in patients with diabetic macular edema (DME) in the ongoing Phase 3 ALTO pivotal program."
• "Our third late-stage asset, KSI-101, is being developed for macular edema secondary to inflammation, or MESI, with our first topline readout from its Phase 3 program expected in December 2026."
• "Together, these three assets reflect the breadth of our late-stage opportunity and ambition to build a leading retinal medicines company with multiple therapies capable of providing meaningful and durable benefits to patients."
• "Todays results are deeply satisfying. Four years and seven months after our first Phase 3 readout, Zenkudas profile has come fully into focus through rigorous science, disciplined learning and thoughtful execution."
• "DAYBREAK demonstrated the attributes we designed Zenkuda to achieve: rapid disease control in wet AMD and the potential for six-month durability under stringent treat-to-dryness retreatment criteria."
• "We plan to submit the BLA for Zenkuda later this year."
• "We also look forward to reporting Phase 3 results from the first MESI study of KSI-101, and we are advancing tabirafusp-ted in diabetic macular edema, a high-inflammation disease, through the ongoing Phase 3 ALTO pivotal program."

Industry Context

StockSavvy.ai notes that the successful completion of Phase 3 trials and the announcement of BLA submissions for Zenkuda and KSI-101 place Kodiak Sciences at the forefront of developing next-generation treatments for major retinal vascular diseases. The focus on extended durability and improved dosing intervals aligns with key unmet needs in the ophthalmology market, potentially challenging the current standard of care like aflibercept.

Comparison to Industry Standards

• Zenkuda demonstrated non-inferiority in vision gains compared to aflibercept at year one in the DAYBREAK study.
• Zenkuda achieved 54% of patients on a 6-month dosing interval, which is a significant improvement over the typical 4-8 week dosing for aflibercept, especially under strict treat-to-dryness criteria.
• Zenkuda's safety profile (0% intraocular inflammation, 0.5% cataract) appears favorable compared to aflibercept's reported rates (0.9% cataract).
• Tabirafusp-ted met its primary vision endpoint (p=0.0036) and anatomical endpoint (p<0.0001) in DAYBREAK, indicating potential efficacy.
• The development of bispecific therapies like tabirafusp-ted (anti-IL-6, VEGF-trap) represents an industry trend to address disease biology beyond VEGF alone, aiming for differentiated efficacy in conditions like DME.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical trial success, advancing two key drug candidates towards potential commercialization and increasing company valuation.
• Patients: Potential for new, more durable, and less frequently dosed treatment options for wet AMD, diabetic retinopathy, and retinal vein occlusion, improving quality of life and visual outcomes.
• Healthcare Providers: Opportunity to offer a new standard of care with Zenkuda, potentially simplifying treatment regimens and improving patient adherence.
• Competitors: Increased competitive pressure in the retinal disease market as Kodiak advances its pipeline.

Next Steps

• Submit a multi-indication BLA for Zenkuda in Q4 2026.
• Announce topline data for KSI-101 in Phase 3 PEAK study in December 2026.
• Submit a BLA for KSI-101 in Q2 2027.
• Continue enrollment in the ALTO Phase 3 study for tabirafusp-ted.
• Conduct post-hoc analyses for tabirafusp-ted to identify patient subgroups benefiting from IL-6 inhibition.

Key Dates

Recommendation

The positive Phase 3 results for Zenkuda and tabirafusp-ted are significant advancements, but the company still faces regulatory hurdles and the inherent risks of drug development and commercialization. While the outlook is strong, a 'hold' recommendation allows for observation of the BLA submission process and market reception before considering a more aggressive stance.

Keywords

wet age-related macular degeneration, Zenkuda, tarcocimab tedromer, tabirafusp-ted, KSI-501, diabetic retinopathy, retinal vein occlusion, ophthalmology